Physician profile
Dewitt M Coleman, JR.
NPI 1821088261
$13,005.10
in general payments reported to CMS, 2019-2025
41 companies · $2,964 in 2025
The $2,964 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $1,244 · 2021: $2,057 · 2022: $2,146 · 2023: $1,515 · 2024: $2,037 · 2025: $2,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,267 · Education: $225 · Consulting Fee: $23.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,267.24 |
| Education | $224.52 |
| Consulting Fee | $23.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,242.36 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,613.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,366.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,063.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $714.04 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $601.31 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Csl Behring | $593.10 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $472.99 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $415.46 | 2019-2025 | Xolair, Xofluza |
| Pfizer INC. | $411.91 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $386.36 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $355.55 | 2023-2025 | Cutaquig |
| Abbvie INC. | $343.97 | 2022-2024 | Rinvoq |
| Grifols USA, LLC | $316.78 | 2020-2025 | Xembify |
| Pharming Healthcare, INC. | $247.87 | 2020-2025 | Ruconest |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $239.15 | 2021-2025 | Tezspire, Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.23 | 2019-2022 | |
| Hospira, INC. | $218.97 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $118.86 | 2024 | Amvuttra |
| Hikma Pharmaceuticals USA | $118.23 | 2022-2025 | Ryaltris |
| Aimmune Therapeutics, INC. | $106.11 | 2021-2022 | |
| Alk-Abello, INC | $105.20 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Galderma Laboratories, L.P. | $100.37 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Incyte Corporation | $67.95 | 2022-2025 | Opzelura |
| Merck Sharp & Dohme LLC | $61.86 | 2021-2023 | |
| Kaleo, INC. | $59.45 | 2019-2022 | |
| Leo Pharma INC. | $56.32 | 2023-2025 | Adbry, Anzupgo |
| Organon LLC | $47.21 | 2025 | |
| Shire North American Group INC | $36.11 | 2019 | |
| Aytu Biopharma, INC. | $33.18 | 2024-2025 | Karbinal |
| Adma Biomanufacturing LLC | $23.66 | 2025 | |
| Lilly USA, LLC | $22.37 | 2025 | Ebglyss |
| Biocryst Pharmaceuticals, INC. | $22.17 | 2020 | |
| Gc Biopharma USA, INC. | $22.07 | 2025 | Alyglo |
| Azurity Pharmaceuticals, INC. | $21.46 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $15.91 | 2022 | |
| Phadia US INC. | $14.98 | 2023 | Immunocap |
| Cycle Pharmaceuticals INC | $14.43 | 2025 | Sajazir |
| Eyevance Pharmaceuticals LLC | $13.07 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewitt Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.